Navigation

Carl Kirkpatrick

Author Archive | Carl Kirkpatrick

Treatment of malaria: from drug discovery to optimisation of current therapies.

January 31, 2012

Authors Julie Simpson , Susan Charman, Joel Tarning
Affiliations Centre of Molecular, Environmental, Genetic & Analytic Epidemiology, The University of Melbourne, Melbourne, Australia, Faculty of Pharmacy & Pharmaceutical Sciences, Monash University, Melbourne, Australia, Clinical Pharmacology Laboratory, Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
Presentation type Oral
Presenters Julie Simpson

  Almost 40% of the world’s population live in malaria endemic areas, with each year about a quarter of a billion people experiencing clinical malaria and an estimated 655,000 deaths. With no vaccine currently available, artemisinin-based combination therapies are the first-line defence against malaria. These therapies have been highly effective worldwide until recent reports from […]

Continue Reading

Mechanism-based modelling of antibiotics to optimally cure patients and prevent resistance: progress, gaps, and future perspectives

January 31, 2012

Authors J
Affiliations 1 Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia , 2 Monash Institute for Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia, 3 School of Pharmacy and Pharmaceutical Sciences, SUNY Buffalo, NY, USA
Presentation type Oral
Presenters Jurgen Bulitta

Attachments
Mechanism-based pharmacodynamic model of a beta-lactam (LAC) beta-lactamase inhibitor (BLI) combination against Eschericia coli

Background: Substantial progress of mechanism-based and empirical modelling for anti-infectives over the past decade has enabled these models to rationally translate the time-course of killing and emergence of resistance from in vitro to animal infection models and ultimately to patients. Objectives: To illustrate applications of translational mechanism-based models for anti-infective mono- and combination therapy and […]

Continue Reading